

Assessing the Use of Prescription Drugs in Obese Respondents in the National Health and Nutrition Examination Survey

Laura A. Barrett, MS¹, Aiwen Xing, MS², Julia Sheffler, PhD³, Elizabeth Steidley¹, Terrence J.
Adam, RPh, MD, PhD⁴, Rui Zhang, PhD⁴, Zhe He, PhD^{1,3}

¹School of Information, Florida State University, Tallahassee, FL, USA

²Department of Statistics, Florida State University, Tallahassee, FL, USA

³Department of Behavioral Sciences and Social Medicine, College of Medicine, Florida State
University, Tallahassee, FL, USA

⁴Institute for Health Informatics and College of Pharmacy, University of Minnesota,
Minneapolis, MN, USA

1

2 **Corresponding Author:**

3 Zhe He, PhD
4 School of Information
5 College of Communication and Information
6 Florida State University
7 142 Collegiate Loop
8 Tallahassee, Florida 32306-2100
9 zhe@fsu.edu
10 Phone: 001(850)644-5775

11

12 **Competing Interests**

13 None

14 **Abstract**

15 **Introduction:** Obesity is a common disease and a known risk factor for many other conditions
16 such as hypertension, type 2 diabetes, and cancer. Treatment options for obesity include lifestyle
17 changes, pharmacotherapy, and surgical interventions such as bariatric surgery. In this study, we
18 examine the use of prescription drugs and dietary supplements by the individuals with obesity.

19 **Methods:** We conducted a cross-sectional analysis of the National Health and Nutrition
20 Examination Survey (NHANES) data 2003-2014. We used multivariate logistic regression to
21 analyze the correlations of demographics and obesity status with the use of prescription drugs
22 and dietary supplement use. We also built machine learning models to classify prescription drug
23 and dietary supplement use using demographic data and obesity status.

24 **Results:** Individuals with obesity are more likely to take cardiovascular agents (OR=1.265, 95%
25 CI 1.222-1.311) and metabolic agents (OR=1.398, 95% CI 1.343-1.456) than individuals without
26 obesity. The best performing model for classifying prescription drug use had the accuracy of
27 74.5% and the AUROC of 0.817.

28 **Conclusions:** This study can inform clinical practice and patient education of the use of
29 prescription drugs and dietary supplements and their correlation with obesity.

30

31 **Introduction**

32 As a major health and economic crisis affecting the modern world, much progress has
33 been made in identifying and developing strategies for preventing and treating obesity.
34 Currently, treatment options include lifestyle changes, pharmacotherapy, and surgical
35 interventions (e.g., intragastric balloons and bariatric surgery).¹ In terms of pharmacotherapy,
36 there are five approved prescription drugs (RXD) (orlistat, 1999; phentermine/topiramate, 2012;
37 liraglutide, 2014; naltrexone/bupropion, 2014; and semaglutide, 2021) that can be prescribed for
38 weight loss.² All but orlistat, which reduces the absorption of fat, work by helping the individual
39 to limit caloric intake.³ There are also four RXD that are similar to amphetamines that can be
40 used short-term (phendimetrazine, diethylpropion, phentermine, and benzphetamine).⁴ There
41 have been three other well-known RXD that were approved for use and then removed from the
42 market. The first one is fenfluramine/phentermine (fen-phen) which was discontinued in 1997
43 because fenfluramine was shown to cause cardiac issues.⁵ The second one is sibutramine, which
44 was withdrawn in 2010 due to an increased risk of stroke and myocardial infarction.⁶ The third
45 one is lorcaserin, which was withdrawn in February 2020 after a clinical trial showed an
46 increased occurrence of cancers.⁷ Due to the cost of pharmacotherapy and surgical interventions,
47 as well as other reasons, dietary supplements (DS) are often used as a cost-sensitive and easily
48 accessible, albeit less scientifically supported, alternative treatment of obesity.^{8,9}

49 Individuals with obesity face an increased risk of chronic diseases, namely depression,
50 type 2 diabetes, cardiovascular disease, and many cancers including those of the colon, breast,
51 kidney, and pancreas.¹⁰ Many of these conditions require pharmaceutical intervention as part of
52 the treatment plan and individuals with obesity often use RXDs to manage these conditions.
53 Overall, RXD use in the United States has increased.⁹ This increase is partly influenced by the

54 development of new RXDs, the expansion of RXD coverage by insurance companies, and
55 increased rates of chronic conditions such as obesity.⁹ The greatest increase in RXD use has been
56 in those used for treating conditions found to be associated with obesity, specifically
57 antihypertensives, antihyperlipidemic, antidiabetics, and antidepressants.¹¹

58 Recent studies have researched obesity in relation to specific drugs or drug types.¹²⁻¹⁶
59 There have also been recent studies that examined various aspects of obesity such as childhood
60 obesity,^{16,17} obesity and hours spent at work,¹⁸ exposure to certain pollutants or chemicals,¹⁹⁻²¹
61 trends in obesity,²² and obesity and waist circumference.²³ However, there have not been any
62 studies that look at overall RXD use in individuals with obesity. Being able to see this bird's eye
63 view of this relationship is important because understanding the patterns of RXD use among
64 people with obesity, who often have other chronic conditions, can inform both clinical practice
65 and research.⁹ This is challenging because there are cross-over issues between RXD, their side
66 effect of weight gain, and their therapeutic effect on obesity and its comorbidities. For example,
67 certain blood-glucose-lowering RXD and psychotropics may lead to unintended weight gain.²⁴ In
68 this project, we aim to gain an in-depth understanding of both the relationship between obesity
69 and RXD use, as well as the correlations between specific RXD and DS use in individuals with
70 obesity. We also aim to understand if demographic variables and obesity status can assist with
71 classifying an individual's likelihood of using any RXD or DS, not just specific RXD or DS.

72 **Materials and Methods**

73 The National Center for Health Statistics of CDC has been conducting the National Health and
74 Nutrition Examination Survey (NHANES) as a continuous cross-sectional health survey.²⁵ It
75 samples the non-institutionalized population of the United States with a stratified multistage
76 probability model and releases results of a set of health surveys, medical examinations, a

77 physical, and laboratory test every two years. Its rigorous quality control ensures high-quality
78 data collection and national representativeness. The NHANES data have been used in many
79 public health and epidemiology studies.²⁶⁻³²

80 Demographic, physical examination, prescription drug (RXD) and dietary supplement
81 (DS) use⁸, and health insurance information were extracted from NHANES for survey years
82 2003 – 2014 (6 survey cycles). This is the same cycle used in a previous study³³ regarding DS
83 use which allowed for comparison. Additionally, starting in 2013-2014 ICD-10 codes were listed
84 with the RXD giving improved information regarding RXD use. The 12-year sample weight (the
85 number of people in the US population that a sample in the combined sample can represent) was
86 calculated according to the analytical guideline of NHANES.²⁵ The obese group is defined as:
87 (1) BMI ≥ 30 kg/m²,³⁴ (2) age ≥ 18 .³⁵ From the original NHANES data, 1937 respondents with
88 no BMI and 32 respondents with no RXD use information were removed from the dataset. Table
89 S1 lists the NHANES file, the NHANES variable names, the associated questions, and how they
90 are referred to in this paper.

91 *Data Analysis*

92 **Basic Characteristics:** A profile for each group was created that included sex, age, race, annual
93 household income, and health insurance status.

94 **Statistical Analysis:** We conducted multivariate logistic regression analyses to assess: 1) the
95 associations between using RXD/DS and variables of interests (i.e., demographic characteristics,
96 poverty income ratio, insurance status, and obesity status) and 2) the associations between taking
97 specific types of RXD and obesity status. Weighted multivariate logistic regression analyses
98 were used to obtain odds ratios (OR) and 95% CIs with 12-year sample weight. All interested
99 variables were introduced in the model first then backward elimination with a threshold of $p =$

100 0.05 was applied to eliminate variables. We kept only the variables that were significant in the
101 initial model in the final model. The significance level was set as 0.05. All statistical analyses
102 were performed by SAS software (SAS Institute Inc), version 9.4.

103 We performed two separate logistic regression analyses. 1) Usage based on the specific
104 number of RXD/DS that the individual used was the dependent variable. Demographic
105 characteristics were included as independent variables to examine whether taking a specific
106 number of RXD/DS was significantly associated with demographic characteristics within non-
107 obese or obese groups separately. This regression evaluated covariates down to the two groups.
108 2) Obesity status and demographic characteristics were included as independent variables to test
109 their associations with taking a specific number of RXD/DS within the whole population. In the
110 second analysis, the dichotomous dependent variable was whether participants were prescribed
111 the specific types of RXD; obesity status was set as independent variable with reference as non-
112 obese group.

113 **Classification Modeling:** We used Weka³⁶ to evaluate different machine learning models for
114 classifying whether a respondent used one or more RXD or DS, respectively. In the first round of
115 the modelling, the variables included age group, sex, BMI category, race, annual household
116 income, and insurance status. As we are also interested in seeing whether DS use would help
117 classify RDX use and vice versa, in the second round of modeling, DS use or RXD use was
118 added as a variable for classifying the use of the other type. A third round of modelling was done
119 using the poverty income ratio (PIR) in place of the annual household income. Lastly, we further
120 evaluated if machine learning models were able to classify how many RXD were used. For this
121 round, we created four groups of RDX count (i.e., 0, 1-2, 3-5, >5). We used feature selection
122 based on correlation (“CorrelationAttributeEval” in Weka) to rank the importance of the

123 variables. We evaluated four major machine learning algorithms including Naïve Bayes, Logistic
 124 Regression, SMO (Weka’s implementation of Support Vector Machine), and Random Forest.
 125 Deep learning techniques were not employed because of the small number of variables in this
 126 dataset. The data was preprocessed to make all numerical data nominal. 10-fold cross validation
 127 was employed. In each fold, 90% of the data was used for training and 10% of the data was used
 128 for testing. The models were compared using overall accuracy, precision, recall, F1-score, and
 129 AUROC.

130 Results

131 *Basic Characteristics*

132 Table 1 shows the basic characteristics of the two groups in regard to their RXD use. There are a
 133 few differences based on obesity status and demographics. In the non-obese group 52.64% of
 134 people report taking 1 or more RXD. The obese group has a higher reported use at 63.68%. In
 135 both groups, females report higher use than males. In addition, RXD use increases with age in
 136 both groups. Race also plays a role in reported RXD use in both groups; Non-Hispanic Whites
 137 have the highest percentages of use while Mexican Americans show the lowest percentages.
 138 Lastly, in both groups, those with health insurance reported higher RXD use than those that
 139 reported not having insurance.

140 **Table 1.** Basic characteristics of the study population

Variable	Non-obese				Obese			
	0 RXD		1 or more RXD		0 RXD		1 or more RXD	
	Weight	%	Weight	%	Weight	%	Weight	%
	Count		Count		Count		Count	
Total	66508809	47.36%	73921759	52.64%	26760055	36.32%	46917732	63.68%
(Total sample count)	10903	49.71%	11090	50.56%	4511	37.74%	7442	62.26%
Gender								
Male	38107616	54.91%	31295757	45.09%	14353846	42.29%	19590434	57.71%

(Male sample count)	6172	54.76%	5099	45.24%	2210	42.43%	2999	57.57%
Female	28401193	39.99%	42626002	60.01%	12406209	31.22%	27327297	68.78%
(Female sample count)	4731	44.12%	5991	55.88%	2301	34.12%	4443	65.88%
Age								
18-24	14836894	70.18%	6304274	29.82%	4660202	71.00%	1903380	29.00%
(18-24 sample count)	3034	76.69%	922	23.31%	948	74.59%	324	25.49%
25-34	16942291	65.69%	8849137	34.31%	7470412	63.24%	4343207	36.76%
(25-34 sample count)	2569	71.18%	1040	28.82%	1220	66.96%	602	33.04%
35-44	14731496	58.57%	10418677	41.43%	6813783	45.62%	8121188	54.38%
(35-44 sample count)	2136	63.89%	1207	36.11%	1034	49.38%	1060	50.62%
45-54	11677424	44.68%	14456138	55.32%	4735950	30.01%	11047591	69.99%
(45-54 sample count)	1546	48.82%	1621	51.18%	699	33.07%	1415	66.93%
55-64	5554943	29.58%	13224166	70.42%	2308369	18.04%	10485145	81.96%
(55-64 sample count)	942	33.04%	1909	66.96%	417	19.75%	1694	80.25%
65-74	1818148	14.32%	10874221	85.68%	570357	7.32%	7222091	92.68%
(65-74 sample count)	419	16.85%	2068	83.15%	140	8.82%	1448	91.18%
75 and over	947610	8.82%	9795144	91.18%	200980	5.03%	3795126	94.97%
(75 and over sample count)	257	9.96%	2323	90.04%	53	5.57%	899	94.43%
Race								
Mexican American	7904327	72.27%	3033546	27.73%	4381332	61.83%	2704766	38.17%
(Mexican American sample count)	2359	65.93%	1219	34.07%	1197	54.19%	1012	45.81%
Other Hispanic	4330888	63.44%	2496048	36.56%	2023727	55.70%	1609763	44.30%
(Other Hispanic sample count)	755	42.85%	1007	57.15%	440	46.07%	515	53.93%
Non-Hispanic White	39765947	40.57%	58255518	59.43%	14217576	29.17%	34528101	70.83%
(Non-Hispanic White sample count)	3888	38.14%	6307	61.86%	1356	27.06%	3655	72.94%
Non-Hispanic Black	7805243	58.33%	5575636	41.67%	4851478	42.92%	6452578	57.08%
(Non-Hispanic Black sample count)	2288	55.11%	1864	44.89%	1296	39.58%	1978	60.42%
Other Race or Multi-Racial	6702401	59.51%	4561010	40.49%	1285941	44.21%	1622523	55.79%
(Other Race or Multi-Racial sample count)	1361	59.02%	945	40.98%	222	44.05%	282	55.95%
Household Income								
\$0 to \$34,999	20270690	48.07%	21898357	51.93%	8968445	36.82%	15386882	63.18%

(\$0 to \$34,999 sample count)	4339	48.86%	4541	51.14%	1953	37.49%	3257	62.51%
\$35,000 to \$74,999	19710293	47.96%	21385868	52.04%	9041692	37.40%	15136891	62.60%
(\$35,000 to \$74,999 sample count)	2969	50.11%	2956	49.89%	1330	39.05%	2076	60.95%
\$75,000 and over	21041758	44.89%	25829035	55.11%	6765778	33.33%	13530986	66.67%
(\$75,000 and over sample count)	2481	47.97%	2691	52.03%	834	35.26%	1531	64.74%
Poverty Income Ratio								
0-1	11886187	57.03%	8955378	42.97%	5219995	43.82%	6691191	56.18%
(0-1 sample count)	2758	57.26%	2059	42.74%	1223	43.84%	1567	56.16%
1.01-2	13989268	50.62%	13647792	49.38%	6417578	39.10%	9996556	60.90%
(1.01-2 sample count)	2661	50.34%	2625	49.66%	1212	39.21%	1879	60.79%
2.01-3	9359020	46.75%	10660719	53.25%	3902815	34.02%	7567837	65.98%
(2.01-3 sample count)	1356	46.84%	1539	53.16%	585	35.01%	1086	64.99%
3.01-4	8145263	47.14%	9132730	52.86%	3344522	35.14%	6173617	64.86%
(3.01-4 sample count)	1687	46.16%	1968	53.84%	670	33.52%	1329	66.48%
4.01-5	16824617	40.22%	25006634	59.78%	5573688	30.32%	12809216	69.68%
(4.01-5 sample count)	1256	41.13%	1798	58.87%	387	30.59%	878	69.41%
Health Insurance*								
Yes	45836430	40.83%	66422640	59.17%	17826007	29.68%	42227916	70.32%
(Yes sample count)	6868	41.18%	9809	58.82%	2783	29.83%	6546	70.17%
No	20600914	73.47%	7439920	26.53%	8918505	65.61%	4675065	34.39%
(No sample count)	1726	65.88%	894	34.12%	2620	74.56%	894	25.44%


141 *Overall insurance coverage was 80.5% covered and 19.5% not covered.

142

143 *Specific RXD Types*

144 For the identified RXD types, we evaluated the association between the specific types of RXD
 145 use and obesity status. Table 2 shows the odds ratio between obese and non-obese group taking
 146 prescription drugs. While looking at the types of RXD, there were differences in use between the
 147 obese and non-obese groups. Cardiovascular agents are the most used RXD type in both groups.

148 This is not surprising given the prevalence of cardiovascular diseases in the United States.
149 Compared with those in the non-obese group, individuals with obesity are more likely to take
150 cardiovascular agents (OR=1.265, 95% CI 1.222-1.311) and metabolic agents (OR=1.398, 95%
151 CI 1.343-1.456). Figure 1 (a) shows a comparison of the cardiovascular agents and the metabolic
152 agents based on percent of the RXD used by each age group. In both types of RXD, the obese
153 population uses more of the RXD in the younger age groups, starting clearly at 25-34. The
154 decrease in usage by obese individuals in the 75+ group may, in part, reflect the potential mixed
155 effects of obesity in old age. Studies indicate that people with higher than normal BMI have
156 lower mortality in the 75+ age group, though this is dependent on many other variables.³⁷⁻³⁹
157 Figure 1(b) shows the more detailed breakdown of CVD RDX use by people who are
158 underweight, normal weight, overweight, and obese.



159
 160 **[Figure 1.** (a) Comparison of RXD used by age group. CVD is cardiovascular drug. MA is
 161 metabolic agent. (b) Comparison of CVD RXD used by different age groups and weight
 162 categories.]

163
 164 **Table 2.** Odds ratios between obese and non-obese group taking prescription drugs

Prescription drugs	Obese (%)	Non-Obese (%)	Odds ratios	95% Wald CL		Pr > ChiSq
				1.222	1.311	
Cardiovascular agents	29.49	26.77	1.265	1.222	1.311	<.0001

Metabolic agents	20.83	17.32	1.398	1.343	1.456	<.0001
Central nervous system agents	15.53	15.85	0.884	0.848	0.921	<.0001
Gastrointestinal agents	5.95	6.81	0.894	0.84	0.951	0.0004
Respiratory agent	5.87	6.10	0.933	0.877	0.993	0.0288
Psychotherapeutic agents	5.77	5.94	0.936	0.883	0.993	0.0276
Hormones/hormone modifiers	5.42	7.84	0.617	0.583	0.654	<.0001
Topical agents	2.66	3.62	0.749	0.688	0.814	<.0001
Anti-infectives	2.37	3.56	0.637	0.584	0.696	<.0001
Coagulation modifiers	1.96	2.22	0.972	0.865	1.092	0.6297
Antineoplastics	0.64	0.87	0.763	0.642	0.907	0.0022

165

166 ***Correlation Analysis of RDX and DS Use with Demographic Characteristics***

167 Examining the correlation between reported RDX use and demographic characteristics for the
 168 non-obese and obese groups, we found a few items of interest. Table S2 shows the results of this
 169 regression analysis. Male from both the non-obese and the obese group were significantly less
 170 likely than female to use RXD ($OR_{control} = 0.572$, 95% CI 0.538-0.607, $OR_{obese} = 0.552$,
 171 95% CI 0.508-0.626). Compared with those individuals with obesity older than 75, adults
 172 younger than 54 were significantly less likely to use RXD. When controlling for all other
 173 variables, non-obese people covered by insurance were around 1.338 times ($p < .0001$ for non-
 174 obese group and $p = 0.0056$ for obese group) as likely to use RXD than those who did not have
 175 any insurance coverage. Specifically, individuals with obesity covered by Medicare were 1.435
 176 times more likely to use RXD ($p < .0001$) than those with no Medicare covered.

177 When looking at the correlation between reported DS use and demographic
 178 characteristics for the non-obese and obese groups, we found a few interesting findings (Table
 179 S3). Within the obese group, Mexican American, other Hispanic, and Non-Hispanic Black, and
 180 Other Races (including multi-racial) were significantly less likely to take DS compared with
 181 Non-Hispanic White. A significant correlation was found between PIR (Poverty income ratio: a
 182 ratio of family income to poverty threshold) and DS use for the control group. Non-obese people

183 with a PIR higher than 4 are more likely to take DS. Individuals with obesity covered by private
 184 insurance, Medicare, and other government insurance were significantly more likely to take DS,
 185 while individuals without obesity covered by insurance were 1.241 times as likely to take DS
 186 than those who were not covered by any insurance while holding other variables constant.

187 We were also interested in how obesity status and demographic characteristics associated
 188 with the use RXD or that of DS within the whole population group (Table 3). Female and older
 189 people were more likely to take RXD or DS. PIR is an interesting factor, as people with higher
 190 PIR were significantly more likely to take DS. For RXD use, only those with PIR ≥ 5 were
 191 found to be statistically significant. This was also the case with the PIR (Poverty income ratio: a
 192 ratio of family income to poverty threshold) showing that those with a PIR higher than 1 are
 193 more likely to take RXD or DS. The higher the PIR is, the higher odds people use DS.
 194 Individuals with obesity were more likely to take RXD (OR= 1.567, 95% CI 1.481-1.658) while
 195 less likely to take DS (OR= 0.769, 95% CI 0.731-0.81) compared with individuals without
 196 obesity.


197 **Table 3.** Reported prescription drug use/dietary supplements use by demographic characteristics
 198 and obesity status correlates.

Variable	RXD use			DS use				
	Odds ratio	95% Wald CL	P value	Odds ratio	95% Wald CL	P value		
Gender								
Male	0.549	0.521	0.578	<.0001	0.562	0.535	0.59	<.0001
Female (reference)	1				1			
Age Group								
18-24	0.105	0.084	0.131	<.0001	0.275	0.234	0.323	<.0001
25-34	0.132	0.107	0.164	<.0001	0.375	0.32	0.438	<.0001
35-44	0.198	0.16	0.246	<.0001	0.421	0.361	0.492	<.0001
45-54	0.335	0.27	0.415	<.0001	0.557	0.478	0.649	<.0001
55-64	0.618	0.497	0.768	<.0001	0.846	0.725	0.986	0.0328
65-74	0.693	0.565	0.85	0.0004	0.884	0.777	1.006	0.0611

75 over (reference)	1				1			
Race								
Mexican American	0.461	0.416	0.511	<.0001	0.614	0.558	0.676	<.0001
Other Hispanic	0.524	0.462	0.594	<.0001	0.786	0.7	0.882	<.0001
Non-Hispanic White (reference)	1				1			
Non-Hispanic Black	0.603	0.554	0.656	<.0001	0.597	0.552	0.647	<.0001
Other Race – Including Multi-Racial	0.528	0.475	0.587	<.0001	0.895	0.811	0.989	0.0287
Poverty Income Ratio								
0-1 (reference)	1				1			
1-2	0.928	0.85	1.014	0.099	1.247	1.15	1.352	<.0001
2-3	1.017	0.922	1.121	0.7419	1.394	1.275	1.524	<.0001
3-4	0.91	0.82	1.009	0.0738	1.637	1.49	1.8	<.0001
4-5	1.09	0.974	1.22	0.1346	1.792	1.616	1.986	<.0001
>=5	1.142	1.035	1.261	0.0081	2.278	2.08	2.495	<.0001
Covered by any insurance								
Yes	1.539	1.304	1.816	<.0001	1.128	1.021	1.247	0.0178
No (reference)	1				1			
Covered by private insurance								
Yes	1.371	1.176	1.597	<.0001	1.3	1.191	1.419	<.0001
No (reference)	1				1			
Covered by Medicare								
Yes	2.937	2.476	3.483	<.0001	1.349	1.189	1.53	<.0001
No (reference)	1				1			
Covered by Medicaid								
Yes	2.109	1.764	2.521	<.0001				
No (reference)	1							
Covered by other government insurance								
Yes	1.91	1.616	2.257	<.0001	1.214	1.086	1.357	0.0007
No (reference)	1				1			
Obesity								
Yes	1.567	1.481	1.658	<.0001	0.769	0.731	0.81	<.0001
No (reference)	1				1			

199
200
201 Figure 2 shows the correlation between age, BMI, and the number of RDX and DS used
202 by both the obese group and non-obese group. Figure 2(a) illustrates the correlation between the
203 average number of RXD used by a respondent and the age groups. Generally, the average

204 number of RXD used by a respondent increased with an increase in age for both non-obese and
205 obese groups. Regardless of age, individuals with obesity generally take more RXD than
206 individuals without obesity. The distribution of the average number of RXD used shows a
207 positive skewness distribution: the average number is greater than the median within each age
208 group. Figure 2(b) illustrates the correlation between the average number of DS used and the age
209 groups. Similarly, the average number of DS used generally increased with an increase in age for
210 both groups, with people aging from 65 to 74 taking the highest number of DS (mean of non-
211 obese vs. obese: 2.28 vs.1.86). However, the difference in average number of DS used between
212 the obese and non-obese groups was not as clear as that between the number of RXD used and
213 age group. Figure 1(c) illustrates the correlation between the number of RXD/DS used and BMI.
214 BMI mainly clustered around 18 to 37 kg/m². People typically take higher numbers of RXD than
215 DS. The largest maximum number of DS used (24) can be found among people with BMI from
216 18 to 22 kg/m². The highest average number of RXD used can be found among people with BMI
217 from 63 to 67 kg/m². As both of the BMI categories from 83 to 87 kg/m² and from 128 to 132
218 kg/m² have only one person included in the sample, no bar shows in the figure, the points
219 indicate the true value among those groups.



220 (c)
221 **Figure 2.** (a) The correlation between the number of RXD used and age; (b) The correlation
222 between the number of DS used and age; (c) the number of RXD/DS used compared to BMI.
223 The shade of color represents the aggregated weights within each age group. The points of line
224 indicate the average number used within each age group. The shade of the color represents the

225 aggregated weights within each age group. The points on the line indicate the average number
226 used within each age group.
227

228 *Classification of RDX Use and DS Use Using Machine Learning*

229 Table S4, S5, S6, S7, and S8 in the Supplementary Material show the detailed results of
230 classifying DS and RXD use. Classification of DS use (binary variable) was not as accurate as
231 classification of RXD use (binary variable). Results from the models run were similar for DS use
232 with the highest overall accuracy being 64.63% and the AUROC at 0.7 (Table S4). The results
233 for RXD use were better, with the highest overall accuracy being 74.27% and the highest
234 AUROC at 0.816 (Table S5). To see if results would change with the addition of the variable DS
235 use (for RXD use classification) and RXD use (for DS classification) the same machine learning
236 algorithms were evaluated again. The overall accuracy and AUROC increased slightly in both
237 DS models (Table S4) and RXD models (Table S5). This shows that adding the extra variable
238 did not make a significant contribution to the classifications. Using the PIR in place of the annual
239 household income also did not significantly change the results for classification of both DS use
240 (Table S6) and RDX use (Table S7). For DS classification, RXD use, insurance status, and sex
241 were the top three important features. For RXD classification, insurance status, DS use, and age
242 were the top three important features. In both cases, BMI category and annual household income
243 were in the least three important features. We further created four groups for RDX count (i.e., 0,
244 1-2, 3-5, >5) and classified samples into one of these groups, using the same models and
245 variables. In this experiment (Table S8), the best model is logistic regression with an AUROC of
246 0.76. Note that multiclass classification is inherently more challenging than binary classification.

247 **Discussion**

248 Individuals with obesity experience increased risk for developing chronic diseases across the
249 lifespan, which are often managed using RXD. Overall, RXD use in the United States has
250 increased,⁹ with the greatest increases seen in the treatment of conditions found to be associated
251 with obesity, specifically antihypertensives, antihyperlipidemic, antidiabetics, and
252 antidepressants.¹¹ Further, many individuals may use DS in addition to or instead of RXD. Given
253 the increases in obesity, RXD use, and DS use, it is important to analyze trends in order to better
254 characterize individuals RXD and DS use in relation to obesity.

255 In this study, we used NHANES data from 2003-2014 to examine RXD and DS use in
256 relation to obesity status. We showed that demographics and obesity status do play a role in
257 usage. In regard to demographic variables, we found that the obese group has a higher reported
258 use of RXD at 63.68%. In both groups, females report higher use than males. In addition, RXD
259 use increases with age in both groups. The difference in usage based on sex is explainable
260 because females tend to have more consistent visits to medical practitioners and typically use
261 more RXD in general, compared to males.⁴⁰ The increase in RDX use shown with age can be
262 explained by increased prevalence in clinical comorbidities as the population gets older and is
263 consistent with prior population studies.⁴¹ The reason why the RDX usage decreases by obese
264 individuals in the 75+ group may be that individuals whose obesity was associated with CVD
265 earlier in life may have higher mortality rates. Another possibility is that higher BMI in older age
266 may be protective, as previous research has suggested. Regardless, our findings further highlight
267 that BMI is not as useful of a health parameter in older adults as it is in young and middle-aged
268 adults, which is consistent with previous research.⁴² The differences in race can be explained by
269 the healthcare and insurance gap seen in minority races.⁴³ The increased use by those that are

270 insured can be explained by an increased use of health care services and the associated increase
271 coverage of RXD.⁴⁴

272 Regarding specific RXD types, cardiovascular agents and metabolic agents were used
273 more by the obese group, while hormone/hormone modifiers and psychotherapeutic RXD usage
274 was higher in the non-obese group. While increased use of cardiovascular and metabolic RXD
275 was expected given the cardiometabolic comorbidities with obesity, higher usage of hormonal
276 and psychotherapeutic RXD in non-obese individuals was surprising. . Prior research has found
277 higher rates of reproductive issues and increases in depression and other mental health disorders
278 associated with obesity;⁴⁵ thus, we would expect higher use of related RXD. One explanation
279 may be the association between high TSH and high BMI and low free-T4 and high BMI. These
280 levels may not be outside of the “normal” range for these values but still cause an increase in
281 BMI which could mean that RXD use would not necessarily be indicated.⁴⁶ In regard to
282 psychotherapeutic RXD, it is possible that individuals with obesity may have unrecognized or
283 undiagnosed mental health issues that are seen as medically related to obesity rather than mental
284 health. For example, unhealthy coping mechanisms, such as increasing food intake or bingeing
285 may be related to undiagnosed depressive symptomatology.⁴⁷

286 In looking at tracking the use of specific RXD prescribed for weight loss, there was a
287 small proportion of the population that utilized these drugs. The problem with further study of
288 these RXD is that many of them were approved outside of the 12-year survey data used in this
289 project. Additionally, many of the drugs used for weight loss are also used for other purposes
290 such as management of diabetes or as a general CNS stimulant. Based on the information
291 available it was unclear why respondents used a specific RXD. This made it difficult to
292 understand and analyze the use of these drugs.

293 When looking at both DS use and RXD use, the population with obesity was more likely
294 to use RXD, but less likely to use DS compared with the non-obesity population. This finding is
295 consistent with a previous report that only 33.9% of adults use DS for weight loss.⁴⁸ Similar
296 results were also obtained regardless of sex, age, and financial status.⁴⁹ However, we found
297 additional novel predictors, such as insurance status. While higher RXD use in obese individuals
298 was expected, lower use of DS was surprising. Given the low percentage of individuals who use
299 DS for weight loss, it is possible that a majority of DS use is related to seeking other purported
300 benefits. For example, there are a plethora of DS marketed toward enhancing brain function or
301 enhancing physical function, which may be more likely to be consumed by either older or non-
302 obese individuals who are already health-conscious.

303 The experiments with machine learning models showed that predictions of RXD and DS
304 use could be improved. Future studies should examine alternative variables that may better
305 predict RXD and DS use. For example, diagnostic information, out-of-pocket costs, and RXD
306 coverage information may provide valuable additional information for understanding these
307 relationships. Validated models of RXD and DS use would provide valuable information that
308 may inform patient education. Further, physicians and other health care providers may be able to
309 use this information to better understand patient trends and to make informed prescribing
310 decisions. In particular, health care providers may benefit from being able to characterize
311 individuals most likely to use DS, as these may go unreported otherwise.

312 Overall, our findings indicate that obesity is associated with higher RXD and lower DS
313 use, but income and age are important demographic factors to consider in this relationship. Since
314 it appears that the more used RXD types are associated with comorbid conditions related to
315 obesity instead of treating obesity directly, there may be opportunities for better health

316 education. This may include expanding education on the benefits of lifestyle changes to
317 minimize both obesity and the impact of common comorbid conditions. Further, the lower
318 observed use of DS in the obese population may offer an opportunity for patient education on DS
319 like omega-3 fatty acids and Vitamin B/B-Complex, which are shown to benefit cardiovascular
320 health, omega-3 fatty acids which are shown to benefit weight loss and to maintain blood sugar,
321 and multivitamin/multiminerals which are shown to impact general overall health.³³
322 Understanding use patterns of DS in obese and non-obese individuals may also provide
323 opportunities for educating patients about potentially harmful or ineffective DS, such as those
324 targeting weight loss specifically.⁵⁰

325 Based on Figures 1 and 2(a), there seems to be a point in the 20-30 age range that would
326 be ideal for addressing obesity proactively and aggressively before it escalates into having
327 comorbidities that require RXD. Additionally, there is an opportunity for better education in
328 those under 20 as studies show that obesity in childhood and adolescence can lead to obesity as
329 an adult.⁵¹ Education has shifted from education on treating obesity to education on prevention
330 of obesity, given that losing small amounts of weight or maintaining a healthy weight are more
331 effective than treating obesity once it has developed.⁵² Future studies should examine how access
332 to healthcare may further impact these relationships, especially in regards to accessing quality
333 obesity prevention education.

334 ***Limitations***

335 In most of the survey cycles used, there was no reason or diagnosis code associated with the
336 report of RXD use. This means that we do not know why a respondent was taking a certain
337 RXD. In addition, only primary category was used to type the various RXD. This means that if
338 an RXD has multiple uses or off-label uses that cross-disease categories, it would not be evident

339 in these results. Further, NHANES does not have information specifically geared towards
340 delineating what may be considered a DS whose main purpose is weight loss. Another limitation
341 is that NHANES is a cross-section survey. It is thus not possible to infer any casual relationships
342 between the variables.

343 ***Future Work***

344 The most recent release of NHANES survey cycle (2017-2018) does include a diagnosis code
345 with the RXD information. A future project that contains richer data in regard to RXD and DS
346 use would provide more insight. Even though national health surveys like NHANES provide
347 enormous opportunities for answering many important health-related questions, they have not
348 been used widely for patient education and informatics research except for a few studies of our
349 own.⁵³⁻⁵⁵ In future work, we plan to build informatics tools such as a data dashboard to visualize
350 various types of analyses of the NHANES data to provide patients, policy makers, and health
351 providers a way to explore RXD and DS use in the general population and certain population
352 subgroups.

353 **Conclusions**

354 As obesity becomes a larger issue and the weight crisis in the United States becomes
355 increasingly detrimental, more needs to be done to understand the overall health status associated
356 with this population and how to educate the public about obesity, its comorbidities, and
357 preventive measures that may help. Knowing how RXD and DS use are different from those
358 without obesity is only the start. Further steps can be taken to understand why there are
359 differences and how the underlying diseases and conditions can be pre-empted in this group.
360 Further knowledge on the association between obesity, DS, and RXD can inform patient
361 education with the help of informatics tools such as data dashboards. Developing models that

362 help us understand the causes of and lifestyle changes needed to change obesity status should
363 improve overall health in the United States.

364

365 **Competing Interests**

366 None

367

References

- 368 1. Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. *Clin Med (Lond)*. 2019
369 May;19(3):205–12.
- 370 2. Yanovski SZ, Yanovski JA. Progress in pharmacotherapy for obesity. *JAMA*. 2021 Jul 13;326(2):129–30.
- 371 3. Gadde KM, Martin CK, Berthoud H-R, Heymsfield SB. Obesity: pathophysiology and management. *J Am*
372 *Coll Cardiol*. 2018 Jan 2;71(1):69–84.
- 373 4. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. *JAMA*.
374 2014 Jan 1;311(1):74–86.
- 375 5. Li R, Serdula MK, Williamson DF, Bowman BA, Graham DJ, Green L. Dose-effect of fenfluramine use on
376 the severity of valvular heart disease among fen-phen patients with valvulopathy. *Int J Obes Relat Metab*
377 *Disord*. 1999 Sep;23(9):926–8.
- 378 6. Li M-F, Cheung BM. Rise and fall of anti-obesity drugs. *World J Diabetes*. 2011 Feb 15;2(2):19–23.
- 379 7. Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with
380 lorcaserin - the FDA's review of the Camellia-Timi 61 trial. *N Engl J Med*. 2020 Sep 10;383(11):1000–2.
- 381 8. Gahche JJ, Bailey RL, Potischman N, Ershow AG, Herrick KA, Ahluwalia N, et al. Federal monitoring of
382 dietary supplement use in the resident, civilian, noninstitutionalized US population, National Health and
383 Nutrition Examination Survey. *J Nutr*. 2018 Aug;148(Suppl 2):1436S-1444S.
- 384 9. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in
385 the United States from 1999–2012. *JAMA*. 2015 Nov 3;314(17):1818–31.
- 386 10. Hruby A, Hu FB. The epidemiology of obesity: a big picture. *Pharmacoeconomics*. 2015 Jul;33(7):673–89.
- 387 11. Randhawa AK, Parikh JS, Kuk JL. Trends in medication use by body mass index and age between 1988 and
388 2012 in the United States. *PLoS One*. 2017 Sep 20;12(9).
- 389 12. Stokes A, Lundberg DJ, Hempstead K, Berry KM, Baker JF, Preston SH. Obesity and incident prescription
390 opioid use in the U.S., 2000-2015. *Am J Prev Med*. 2020 Jun;58(6):766–75.
- 391 13. Khalil H, Ellwood L, Lord H, Fernandez R. Pharmacological treatment for obesity in adults: an umbrella
392 review. *Ann Pharmacother*. 2020 Jul;54(7):691–705.

- 393 14. Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized
394 controlled trials of anti-obesity drugs. *Expert Rev Clin Pharmacol*. 2020 Jan;13(1):53–64.
- 395 15. Squadrito F, Rottura M, Irrera N, Minutoli L, Bitto A, Barbieri MA, et al. Anti-obesity drug therapy in clinical
396 practice: Evidence of a poor prescriptive attitude. *Biomed Pharmacother*. 2020 Aug;128.
- 397 16. Srivastava SB. Is there a prescription to treat pediatric obesity? *Am J Lifestyle Med*. 2020 Feb;14(1):36–9.
- 398 17. Uche UI, Suzuki S, Fulda KG, Zhou Z. Environment-wide association study on childhood obesity in the U.S.
399 *Environ Res*. 2020 Dec;191.
- 400 18. Doerrmann C, Oancea SC, Selya A. The association between hours spent at work and obesity status: results
401 from NHANES 2015 to 2016. *Am J Health Promot*. 2020 May;34(4):359–65.
- 402 19. Liao S, Wu N, Gong D, Tang X, Yin T, Zhang H, et al. Association of aldehydes exposure with obesity in
403 adults. *Ecotoxicol Environ Saf*. 2020 Sep 15;201.
- 404 20. Wu B, Jiang Y, Jin X, He L. Using three statistical methods to analyze the association between exposure to 9
405 compounds and obesity in children and adolescents: NHANES 2005-2010. *Environ Health*. 2020 Aug
406 31;19(1).
- 407 21. Zhang Y, Dong T, Hu W, Wang X, Xu B, Lin Z, et al. Association between exposure to a mixture of phenols,
408 pesticides, and phthalates and obesity: Comparison of three statistical models. *Environ Int*. 2019
409 Feb;123:325–36.
- 410 22. Palmer MK, Toth PP. Trends in lipids, obesity, metabolic syndrome, and diabetes mellitus in the united states:
411 an NHANES analysis (2003-2004 to 2013-2014). *Obesity (Silver Spring)*. 2019 Feb;27(2):309–14.
- 412 23. Kim D, Hou W, Wang F, Arcan C. Factors affecting obesity and waist circumference among us adults. *Prev
413 Chronic Dis*. 2019 Jan 3;16.
- 414 24. Hodish I. Insulin therapy, weight gain and prognosis. *Diabetes, Obesity and Metabolism*. 2018 Sep
415 1;20(9):2085–92.
- 416 25. NHANES Survey Methods and Analytic Guidelines [Internet]. [cited 2021 Mar 9]. Available from:
417 <https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx>
- 418 26. Gelfand A, Tangney CC. Analyses and interpretation of cannabis use among NHANES adults. *European
419 Journal of Preventive Cardiology*. 2018 Jan 1;25(1):40–1.
- 420 27. Yu X, Hao L, Crainiceanu C, Leroux A. Occupational determinants of physical activity at work: Evidence
421 from wearable accelerometer in 2005-2006 NHANES. *SSM Popul Health*. 2022 Mar;17.
- 422 28. Casillas A, Liang L-J, Vassar S, Brown A. Culture and cognition-the association between acculturation and
423 self-reported memory problems among middle-aged and older latinos in the National Health and Nutrition
424 Examination Survey (NHANES), 1999 to 2014. *J Gen Intern Med*. 2022 Jan;37(1):258–60.
- 425 29. Perez-Lasierra JL, Casajus JA, González-Agüero A, Moreno-Franco B. Association of physical activity levels
426 and prevalence of major degenerative diseases: Evidence from the national health and nutrition examination
427 survey (NHANES) 1999-2018. *Exp Gerontol*. 2022 Feb;158.
- 428 30. Wang L, Fu Z, Zheng J, Wang S, Ping Y, Gao B, et al. Exposure to perchlorate, nitrate and thiocyanate was
429 associated with the prevalence of cardiovascular diseases. *Ecotoxicol Environ Saf*. 2022 Jan 6;230.

- 430 31. Dong L, Xie Y, Zou X. Association between sleep duration and depression in US adults: A cross-sectional
431 study. *J Affect Disord.* 2022 Jan 1;296:183–8.
- 432 32. Xu Z, Gong R, Luo G, Wang M, Li D, Chen Y, et al. Association between vitamin D3 levels and insulin
433 resistance: a large sample cross-sectional study. *Sci Rep.* 2022 Jan 7;12(1).
- 434 33. He Z, Barrett LA, Rizvi R, Tang X, Payrovnaziri SN, Zhang R. Assessing the use and perception of dietary
435 supplements among obese patients with National Health and Nutrition Examination Survey. *AMIA Jt*
436 *Summits Transl Sci Proc.* 2020 May 30;2020:231–40.
- 437 34. Centers for Disease Control and Prevention. Defining adult overweight and obesity [Internet]. Centers for
438 Disease Control and Prevention. 2021 [cited 2022 Feb 3]. Available from:
439 <https://www.cdc.gov/obesity/adult/defining.html>
- 440 35. Suh E. Age of majority by state in 2022 [Internet]. Policygenius. 2021 [cited 2022 Feb 3]. Available from:
441 <https://www.policygenius.com/estate-planning/age-of-majority-by-state/>
- 442 36. Frank E, Hall M, Trigg L, Holmes G, Witten IH. Data mining in bioinformatics using Weka. *Bioinformatics.*
443 2004 Oct 12;20(15):2479–81.
- 444 37. Stessman J, Jacobs JM, Ein-Mor E, Bursztyn M. Normal body mass index rather than obesity predicts greater
445 mortality in elderly people: the Jerusalem longitudinal study. *Journal of the American Geriatrics Society.*
446 2009;57(12):2232–8.
- 447 38. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity
448 using standard body mass index categories: a systematic review and meta-analysis. *JAMA.* 2013 Jan
449 2;309(1):71–82.
- 450 39. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight,
451 and obesity. *JAMA.* 2005 Apr 20;293(15):1861–7.
- 452 40. Ashman JJ, Hing E, Talwalkar A. Variation in physician office visit rates by patient characteristics and state,
453 2012. *NCHS Data Brief.* 2015 Sep;(212):1–8.
- 454 41. Martin CB, Hales CM, Gu Q, Ogden CL. Prescription drug use in the United States, 2015–2016 [Internet].
455 2019 May [cited 2021 Aug 2]. Report No.: 334. Available from:
456 <http://www.cdc.gov/nchs/products/databriefs/db334.htm>
- 457 42. Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, Lopez-Jimenez F. Diagnostic accuracy of
458 body mass index to identify obesity in older adults: NHANES 1999–2004. *Int J Obes.* 2016 May;40(5):761–7.
- 459 43. Kirby JB, Taliaferro G, Zuvekas SH. Explaining racial and ethnic disparities in health care. *Med Care.* 2006
460 May;44(5 Suppl):I64-72.
- 461 44. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-
462 2008. National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of
463 Health and Human Services; 2010 Sep. Report No.: 42.
- 464 45. de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta-
465 analysis of community-based studies. *Psychiatry Res.* 2010 Jul 30;178(2):230–5.
- 466 46. Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, Ovesen L, et al. Small differences in thyroid
467 function may be important for body mass index and the occurrence of obesity in the population. *J Clin*
468 *Endocrinol Metab.* 2005 Jul;90(7):4019–24.

- 469 47. Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. *Obesity Research*.
470 1995;3(S4):477S-480S.
- 471 48. Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for
472 weight loss in the United States: Results of a national survey. *Obesity*. 2008;16(4):790–6.
- 473 49. Lubowiecki-Vikuk A, Król-Zielińska M, Kantanista A. Consumption of dietary supplements to support
474 weight reduction in adults according to sociodemographic background, body mass index, waist-hip ratio, body
475 fat and physical activity. *Journal of Health, Population and Nutrition* [Internet]. 2019 Nov 5 [cited 2021 Aug
476 2];38(1). Available from: <https://doi.org/10.1186/s41043-019-0191-3>
- 477 50. Office of Dietary Supplements - dietary supplements for weight loss [Internet]. [cited 2021 Aug 2]. Available
478 from: <https://ods.od.nih.gov/factsheets/WeightLoss-HealthProfessional/>
- 479 51. Simmonds M, Burch J, Llewellyn A, Griffiths C, Yang H, Owen C, et al. The use of measures of obesity in
480 childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic
481 review and meta-analysis. *Health Technol Assess*. 2015 Jun;19(43).
- 482 52. Gill T, King L, Caterson I. Obesity prevention: necessary and possible. A structured approach for effective
483 planning. *Proc Nutr Soc*. 2005 May;64(2):255–61.
- 484 53. He Z, Wang S, Borhanian E, Weng C. Assessing the collective population representativeness of related type 2
485 diabetes trials by combining public data from clinicaltrials.gov and NHANES. *Stud Health Technol Inform*.
486 2015;216:569–73.
- 487 54. He Z, Ryan P, Hoxha J, Wang S, Carini S, Sim I, et al. Multivariate analysis of the population
488 representativeness of related clinical studies. *J Biomed Inform*. 2016 Apr;60:66–76.
- 489 55. He Z, Charness N, Bian J, Hogan WR. Assessing the comorbidity gap between clinical studies and prevalence
490 in elderly patient populations. *IEEE EMBS Int Conf Biomed Health Inform*. 2016 Feb;2016:136–9.
- 491
- 492

493 **Figure Caption**

494

495 **Figure 1.** (a) Comparison of RXD used by age group. CVD is cardiovascular drug. MA is
496 metabolic agent. (b) Comparison of CVD RXD used by different age groups and weight
497 categories.

498

499

500 **Figure 2.** (a) The correlation between the number of RXD used and age; (b) The correlation
501 between the number of DS used and age; (c) the number of RXD/DS used compared to BMI.
502 The shade of color represents the aggregated weights within each age group. The points of line
503 indicate the average number used within each age group. The shade of the color represents the
504 aggregated weights within each age group. The points on the line indicate the average number
505 used within each age group.

506

507

508 **Table Caption**

509

510 **Table 1.** Basic characteristics of the study population

511

512 **Table 2.** Odds ratios between obese and non-obese group taking prescription drugs

513

514 **Table 3.** Reported prescription drug use/dietary supplements use by demographic characteristics
515 and obesity status correlates.

516

517

518 **Supporting Information**

519

520 **Table S1.** NHANES Variables

521 **Table S2.** Reported prescription drug use by demographic characteristics among obese and
522 control group.

523 **Table S3.** Reported prescription dietary supplements use by demographic characteristics among
524 obese and control group.

525 **Table S4.** Performance of machine learning models for classifying DS use

526 **Table S5.** Performance of machine learning models for classifying RXD use

527 **Table S6.** Performance of machine learning models for classifying DS use using PIR

528 **Table S7.** Performance of machine learning models for classifying RXD use using PIR

529 **Table S8.** Performance of machine learning models for classifying RXD use into categories

530